INTEGRA: A Vanguard Study of Health Service Delivery in a Mobile Health Delivery Unit
Public ClinicalTrials.gov record NCT04804072. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
INTEGRA: A Vanguard Study of Health Service Delivery in a Mobile Health Delivery Unit to Link Persons Who Inject Drugs to Integrated Care and Prevention for Addiction, HIV, HCV and Primary Care
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to determine the efficacy of using a mobile health delivery unit ("mobile unit") to deliver "one stop" integrated health services - particularly medication for opioid use disorder (MOUD) and medication for HIV treatment and prevention - to people who inject drugs (PWID) with opioid use disorder (OUD) to improve uptake and use of MOUD, and uptake and use of antiretroviral therapy (ART) or pre-exposure prophylaxis (PrEP).
Study identification
- NCT ID
- NCT04804072
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Not applicable
- Enrollment
- 447 participants
Conditions and interventions
Conditions
Interventions
- Medication for opioid-use disorder (MOUD) for opioid-use disorder (OUD) Drug
- HIV testing Diagnostic Test
- HIV treatment for participants living with HIV not already in care Drug
- PrEP for participants without HIV Drug
- Testing and referral for vaccination or treatment for hepatitis A virus (HAV) and hepatitis B virus (HBV) Diagnostic Test
- Testing and referral for treatment for hepatitis C virus (HCV) Diagnostic Test
- Sexually transmitted infection (STI) testing and treatment Diagnostic Test
- Primary care Other
- Harm reduction services Behavioral
- Peer navigation Behavioral
- COVID-19 testing and referral for further evaluation, care and/or treatment Diagnostic Test
Drug · Diagnostic Test · Other + 1 more
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 1, 2021
- Primary completion
- Dec 16, 2024
- Completion
- Dec 16, 2024
- Last update posted
- Jun 9, 2026
2021 – 2024
United States locations
- U.S. sites
- 5
- U.S. states
- 5
- U.S. cities
- 5
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UCLA Vine Street Clinic | Los Angeles | California | 90095 | — |
| George Washington University CRS | Washington D.C. | District of Columbia | 20007 | — |
| Bronx Prevention Center CRS | The Bronx | New York | 10451 | — |
| Penn Prevention CRS | Philadelphia | Pennsylvania | 19104 | — |
| Houston AIDS Research Team CRS | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04804072, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 9, 2026 · Synced Sep 4, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04804072 live on ClinicalTrials.gov.